Skip to main content
SpringerLink
Log in

Wann doppelt, wann dreifach gegen HCV?

Chronische Hepatitis C

  • SEMINAR
  • FORTBILDUNG
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Deutschlandweit sind etwa 400 000 bis 500 000 Menschen chronisch mit dem Hepatitis-C-Virus (HCV) infiziert. Die Gefahr dieser Infektion besteht in ihrem progressiven Verlauf, mit dem Risiko der Zirrhoseentstehung, der Entwicklung eines hepatozellulären Karzinoms und der Notwendigkeit einer Lebertransplantation [1].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur (

  1. Sarrazin, C., et al., [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol, 2010. 48(2): p. 289–351.

    Article  PubMed  CAS  Google Scholar 

  2. Sarrazin, C., et al., [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol, 2012. 50(1): p. 57–72.

    Article  PubMed  CAS  Google Scholar 

  3. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements, 2002. 19(3): p. 1–46.

  4. Pawlotsky, J.M., Use and interpretation of virological tests for hepatitis C. Hepatology, 2002. 36(5 Suppl 1): p. S65–73.

    Article  PubMed  Google Scholar 

  5. Ferreira-Gonzalez, A. and M.L. Shiffman, Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis, 2004. 24 Suppl 2: p. 9–18.

    Article  PubMed  CAS  Google Scholar 

  6. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep, 2001. 50(RR-5): p. 1–43.

  7. Scott, J.D. and D.R. Gretch, Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA, 2007. 297(7): p. 724–32.

    Article  PubMed  CAS  Google Scholar 

  8. Clark, P.J., A.J. Thompson, and J.G. McHutchison, IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol, 2011. 106(1): p. 38–45.

    Article  PubMed  CAS  Google Scholar 

  9. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol, 2011. 55(2): p. 245–64.

    Google Scholar 

  10. Manns, M.P., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001. 358(9286): p. 958–65.

    Article  PubMed  CAS  Google Scholar 

  11. Sherman, K.E., et al., Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med, 2011. 365(11): p. 1014–24.

    Article  PubMed  CAS  Google Scholar 

  12. Poordad, F., et al., Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 2011. 364(13): p. 1195–206.

    Article  PubMed  CAS  Google Scholar 

  13. Kwo, P.Y., et al., Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 2010. 376(9742): p. 705–16.

    Article  PubMed  CAS  Google Scholar 

  14. Bacon, B.R., et al., Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med, 2011. 364(13): p. 1207–17.

    Article  PubMed  CAS  Google Scholar 

  15. Jacobson, I.M., et al., Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology, 2012. 56(2): p. 567–75.

    Article  PubMed  CAS  Google Scholar 

  16. McHutchison, J.G., et al., Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med, 2009. 360(18): p. 1827–38.

    Article  PubMed  CAS  Google Scholar 

  17. Smith, L.S., et al., Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother, 2011. 45(5): p. 639–48.

    Article  PubMed  CAS  Google Scholar 

  18. McHutchison, J.G., et al., Telaprevir for previously treated chronic HCV infection. N Engl J Med, 2010. 362(14): p. 1292–303.

    Article  PubMed  CAS  Google Scholar 

  19. Zeuzem, S., et al., Telaprevir for retreatment of HCV infection. N Engl J Med, 2011. 364(25): p. 2417–28.

    Article  PubMed  CAS  Google Scholar 

  20. Jacobson, I.M., et al., Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med, 2011. 364(25): p. 2405–16.

    Article  PubMed  CAS  Google Scholar 

  21. Kiser, J.J., et al., Review and management of drug interactions with boceprevir and telaprevir. Hepatology, 2012. 55(5): p. 1620–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar Technische Universität München, Ismaninger Str.22, D-81675, München, Deutschland

    Philipp Thies

Authors
  1. Philipp Thies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Geisler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Thies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thies, P., Schmid, M. & Geisler, F. Wann doppelt, wann dreifach gegen HCV?. MMW - Fortschritte der Medizin 154, 59–63 (2012). https://doi.org/10.1007/s15006-012-1347-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-012-1347-x

Keywords - Diagnosis and treatment of hepatitis C

Search

Navigation